据知情人士透露，默沙东（MRK）与Terns Pharmaceuticals, Inc.（TERN）的并购协商已进入关键阶段。双方正就最终条款进行密集磋商，若进展顺利，这项备受市场关注的交易有望在未来数日内正式敲定。
业内人士分析指出，此次谈判快速推进反映出默沙东对Terns在非酒精性脂肪性肝炎（NASH）领域创新疗法的强烈兴趣。若交易达成，将显著增强默沙东在代谢疾病领域的研发管线布局。
资本市场对潜在交易反应积极。近期Terns股价持续走高，显示投资者对并购前景持乐观态度。而默沙东作为全球制药巨头，通过此次收购有望进一步巩固其在肝病治疗领域的战略地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.